| Literature DB >> 29422913 |
Diego Garzón-Ospina1,2, Sindy P Buitrago1, Andrea E Ramos1, Manuel A Patarroyo1,3.
Abstract
Parasite antigen genetic diversity represents a great obstacle when designing a vaccine against malaria caused by Plasmodium vivax. Selecting vaccine candidate antigens has been focused on those fulfilling a role in invasion and which are conserved, thus avoiding specific-allele immune responses. Most antigens described to date belong to the blood stage, thereby blocking parasite development within red blood cells, whilst studying antigens from other stages has been quite restricted. Antigens from different parasite stages are required for developing a completely effective vaccine; thus, pre-erythrocyte stage antigens able to block the first line of infection becoming established should also be taken into account. However, few antigens from this stage have been studied to date. Several P. falciparum sporozoite antigens are involved in invasion. Since 77% of genes are orthologous amongst Plasmodium parasites, P. vivax sporozoite antigen orthologs to those of P. falciparum might be present in its genome. Although these genes might have high genetic diversity, conserved functionally-relevant regions (ideal for vaccine development) could be predicted by comparing genetic diversity patterns and evolutionary rates. This study was thus aimed at searching for putative P. vivax sporozoite genes so as to analyse their genetic diversity for determining their potential as vaccine candidates. Several DNA sequence polymorphism estimators were computed at each locus. The evolutionary force (drift, selection and recombination) drawing the genetic diversity pattern observed was also determined by using tests based on polymorphism frequency spectrum as well as the type of intra- and inter-species substitutions. Likewise, recombination was assessed both indirectly and directly. The results showed that sporozoite genes were more conserved than merozoite genes evaluated to date. Putative domains implied in cell traversal, gliding motility and hepatocyte interaction had a negative selection signal, being conserved amongst different species in the genus. PvP52, PvP36, PvSPATR, PvPLP1, PvMCP1, PvTLP, PvCelTOS, and PvMB2 antigens or functionally restricted regions within them would thus seem promising vaccine candidates and could be used when designing a pre-erythrocyte and/or multi-stage vaccine against P. vivax to avoid allele-specific immune responses that could reduce vaccine efficacy.Entities:
Keywords: Plasmodium vivax; genetic diversity; hepatocyte invasion; natural selection; sporozoite; vaccine
Year: 2018 PMID: 29422913 PMCID: PMC5788960 DOI: 10.3389/fgene.2018.00010
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
In silico characterization of 14 P. vivax sporozoite proteins.
| Yes (1–22) | No | No | – | Secretory | |
| Yes (1–18) | No | C-ter | Sexual stage antigen s48/45 domain (159–281) | Secretory/membrane | |
| No | Yes (10–32 and 37–59) | No | Sexual stage antigen s48/45 domain (204–332) | Secretory/membrane | |
| Yes (1–20) | No | No | – | Secretory | |
| Yes (1–18) | Yes (131–154) | C-ter | Thrombospondin type 1 domain (59–105) | Secretory/membrane | |
| Yes (1–24) | Yes (494–515) | No | von Willebrand factor type A domain (44–225) and Thrombospondin type 1 domain (241–284) | Secretory/membrane | |
| Yes (1–19) | No | No | – | Secretory | |
| No | Yes (7–28) | No | – | Secretory | |
| Yes (1–19) | Yes (1,799–1,816) | No | – | Secretory/membrane | |
| Yes (1–23) | Yes (7–26) | No | Membrane attack complex/perforin (MACPF) (232–581) | Secretory | |
| No | No | No | AhpC/TSA family (9–134) | Non cytoplasmic | |
| Yes (1–23) | Yes (1,426–1,445) | No | Thrombospondin type 1 domain (264–311) and von Willebrand factor type A domain (334–508) | Secretory/membrane | |
| Yes (1–35) | No | No | – | Non cytoplasmic | |
| Yes (1–22) | No | No | Elongation factor Tu GTP binding domain (766–931) and Translation-initiation factor 2 (1,151–1,263) | Secretory |
The key structures for a potential vaccine candidate (such as a signal peptide, a transmembrane helix or glycosylphosphatidylinositol (GPI) anchor and functional domains) were described from the P. vivax Sal–I strain aa sequence. A protein's type of cell location is also indicated. The numbers in brackets indicate the position where a determined structure was predicted.
Figure 1Schematic models for Plasmodium vivax sporozoite antigen encoding genes and their predicted functionally constrained regions. The 14 putative P. vivax sporozoite antigens were characterized in silico. Each antigen's predicted structure is shown in different colors and the predicted regions under functional constraint (highly conserved between species, having a ω < 1 and several negatively selected codons) are enclosed by a black dashed rectangle. In most cases, these regions correspond with regions having a putative domain. A region encoding a transmembrane helix was predicted for pvp36 and pvsiap2 at the 5′-end, but this could have been a misleading prediction (i.e., it could actually have been a signal peptide).
Estimating 14 P. vivax sporozoite genes' genetic diversity.
| 15 | 2,991 | 12 | 8 | 4 | 8 | 2.55 | 0.0012 (0.0005) | 0.0008 (0.0002) | 2.00 | 0.0020 | |
| 86 | 1,461 | 9 | 2 | 7 | 13 | 1.98 | 0.0012 (0.0012) | 0.0014 (0.0001) | 1.49 | 0.0031 | |
| 102 | 1,059 | 6 | 3 | 3 | 9 | 1.13 | 0.0011 (0.0005) | 0.0011 (0.0001) | 0.67 | 0.0019 | |
| 91 | 822 | 4 | 2 | 2 | 5 | 0.21 | 0.0009 (0.0005) | 0.0003 (0.0001) | 0.09 | 0.0003 | |
| 63 | 480 | 2 | 0 | 2 | 3 | 0.59 | 0.0009 (0.0006) | 0.0012 (0.0002) | 0.59 | 0.0037 | |
| 81 | 1,668 | 28 | 9 | 19 | 20 | 5.11 | 0.0036 (0.0011) | 0.0031 (0.0002) | 3.91 | 0.0070 | |
| 86 | 723 | 1 | 0 | 1 | 2 | 0.05 | 0.0003 (0.0003) | 0.0001 (0.0000) | 0.05 | 0.0002 | |
| 79 | 1,239 | 25 | 8 | 17 | 25 | 2.09 | 0.0041 (0.0013) | 0.0017 (0.0002) | 1.99 | 0.0048 | |
| 12 | 5,598 | 25 | 22 | 3 | 6 | 5.15 | 0.0015 (0.0006) | 0.0009 (0.0005) | 2.49 | 0.0013 | |
| 73 | 2,529 | 13 | 5 | 8 | 14 | 0.77 | 0.0011 (0.0004) | 0.0003 (0.0001) | 0.40 | 0.0004 | |
| 92 | 1,455 | 13 | 4 | 9 | 19 | 1.44 | 0.0020 (0.0007) | 0.0009 (0.0001) | 0.84 | 0.0017 | |
| 57 | 4,308 | 25 | 11 | 14 | 16 | 2.45 | 0.0013 (0.0004) | 0.0006 (0.0001) | 1.68 | 0.0012 | |
| 101 | 588 | 6 | 3 | 3 | 10 | 0.89 | 0.0020 (0.0009) | 0.0015 (0.0002) | 0.76 | 0.0039 | |
| 45 | 4,044 | 35 | 16 | 19 | 30 | 5.08 | 0.0020 (0.0006) | 0.0012 (0.0001) | 2.28 | 0.0017 |
The genetic diversity estimators were calculated from a variable amount of sequences for each antigen. n: amount of sequences analyzed. Sites, total of sites analyzed, excluding gaps; Ss, amount of segregating sites; S, amount of singleton sites; Ps, amount of informative-parsimonious sites; H, amount of haplotypes; ƙ.
Neutrality and codon usage bias tests.
| −1.20 | −1.71 | −1.84 | −0.44 | 0.000(0.000) | −0.153(0.010) | 13.6 | 52.0 | 0.27 | |
| 0.27 | 1.29 | 0.94 | −2.93 | 0.000(0.000) | −0.023(0.003) | 2.87 | 53.6 | 0.22 | |
| −0.36 | −1.80 | −1.79 | 0.44 | −0.001(0.002) | −0.023(0.003) | 3.82 | 54.2 | 0.23 | |
| −1.42 | −1.47 | −1.71 | −0.22 | −0.001(0.001) | −0.034(0.005) | 1,56 | 49.6 | 0.39 | |
| 0.64 | 0.72 | 0.81 | 0.46 | 0.002(0.001) | −0.007(0.005) | Null | 50.7 | 0.45 | |
| −0.48 | −0.24 | −0.36 | −11.61 | 0.002(0.001) | −0.014(0.004) | 6.46 | 55.8 | 0.20 | |
| −0.91 | 0.50 | 0.09 | 0.04 | 0.000(0.000) | −0.014(0.003) | Null | 47.5 | 0.29 | |
| −1.80 | −0.75 | −1.35 | −2.07 | 0.002(0.001) | −0.003(0.003) | Null | 47.5 | 0.36 | |
| −1.68 | −1.20 | −1.64 | −10.21 | −0.001(0.000) | −0.066(0.007) | 0.39 | 49.1 | 0.30 | |
| −2.11 | −0.78 | −1.46 | −3.16 | −0.002(0.001) | −0.033(0.003) | 2.09 | 52.3 | 0.28 | |
| −1.19 | −1.44 | −1.64 | 0.57 | −0.001(0.001) | −0.045(0.005) | 1.64 | 47.8 | 0.28 | |
| −1.76 | −1.39 | −1.95 | −5.22 | −0.0001(0.000) | −0.051(0.004) | 1.81 | 52.7 | 0.20 | |
| −0.80 | −0.82 | −0.87 | −1.49 | 0.001(0.001) | −0.036(0.0027) | 6.36 | 53.8 | 0.35 | |
| −1.31 | −1.67 | −1.84 | −3.41 | −0.001(0.001) | −0.074(0.004) | 1.26 | 53.4 | 0.25 | |
Selective pressure on each gene was inferred from neutrality tests and estimating effective codon usage. Non-synonymous substitution rate (dN) and synonymous substitution rate (dS) in P. vivax. Non-synonymous (KN) and synonymous (KS) divergence between P. vivax and the phylogenetically closest specie. Neutrality index (NI) estimated by McDonald-Kreitman test, using Jukes-Cantor correction. The preferential use of the synonymous codons was evaluated by estimating the effective amount of codons (ENC) and the codon bias index (CBI). Genes under selection in the tests had
p < 0.05,
p < 0.01,
p < 0.03,
p < 0.006, and
p < 0.0001.
LD and intra-gene recombination estimators.
| 0.12 | −0.00 | 1 | – | |
| 0.08 | −0.06 | 2 | 369 | |
| 0.01 | −0.00 | 1 | – | |
| 0.54 | 0.18 | 0 | – | |
| 0.04 | 0.00 | 0 | – | |
| 0.10 | 0.06 | 22 | 1,200 | |
| – | – | – | – | |
| 0.03 | −0.02 | 2 | – | |
| 0.73 | 0.16 | 0 | – | |
| 0.03 | −0.01 | 2 | 1,275 | |
| 0.02 | −0.02 | 2 | – | |
| 0.08 | 0.12 | 2 | 2,551 | |
| 0.02 | 0.01 | 0 | 355 | |
| 0.04 | 0.04 | 7 | 1,368 |
GARD, recombination breakpoint position.
p < 0.04,
p < 0.005,
p < 0.001.